developing a portfolio of
oral medicines to transform the patient experience

KalVista is building a pipeline of novel oral, small molecule protease inhibitors through preclinical and clinical development as potential best-in-class treatments for a range of diseases, beginning with hereditary angioedema (HAE).

Our lead drug investigational product, sebetralstat, has the potential to be the first oral on-demand treatment for HAE and is designed to offer patients a new way to manage HAE. We are also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management.

See Our Phase 3 Data
for Sebetralstat

All our drug programs are internally developed by our R&D team, resulting in full rights and long-term patent protection.